Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy
Research · 2024-01 · 7
DOI: 10.34133/research.0488 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Research, online erschienen am 25.09.2024. Verfasst von Shengbo Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research…. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Immune checkpoint therapy, such as programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blockade, has achieved remarkable results in treating various tumors. However, most cancer patients show a low response rate to PD-1/PD-L1 blockade, especially those with microsatellite stable/mismatch repair-proficient colorectal cancer subtypes, which indicates an urgent need for new approaches to augment the efficacy of PD-1/PD-L1 blockade. Cholesterol metabolism, which involves generating multifunctional metabolites and essential membrane components, is also instrumental in tumor development. In recent years, inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine proteinase that regulates cholesterol metabolism, has been demonstrated to be a method enhancing the antitumor effect of PD-1/PD-L1 blockade to some extent. Mechanistically, PCSK9 inhibition can maintain the recycling of major histocompatibility protein class I, promote low-density lipoprotein receptor-mediated T-cell receptor recycling and signaling, and modulate the tumor microenvironment (TME) by affecting the infiltration and exclusion of immune cells. These mechanisms increase the quantity and enhance the antineoplastic effect of cytotoxic T lymphocyte, the main functional immune cells involved in anti-PD-1/PD-L1 immunotherapy, in the TME. Therefore, combining PCSK9 inhibition therapy with anti-PD-1/PD-L1 immunotherapy may provide a novel option for improving antitumor effects and may constitute a promising research direction. This review concentrates on the relationship between PCSK9 and cholesterol metabolism, systematically discusses how PCSK9 inhibition potentiates PD-1/PD-L1 blockade for cancer treatment, and highlights the research directions in this field.
Autor:innen und Institutionen
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing, China.
- Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- College of Biological Sciences and Technology, Yili Normal University, Yining, China.
ORCID-Profile: Zhengyang Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, S., Ma, J., Zuo, T., Shi, J., Sun, L., Meng, C., Shu, W., Yang, Z., Yao, H., & Zhang, Z. (2024). Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy. Research, 7. https://doi.org/10.34133/research.0488
Vancouver
Sun S, Ma J, Zuo T, Shi J, Sun L, Meng C, et al. Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy. Research. 2024;7. doi:10.34133/research.0488
BibTeX
@article{Sun2024,
author = {Sun, Shengbo and Ma, Jingxin and Zuo, Tingting and Shi, Jinyao and Sun, Liting and Meng, Cong and Shu, Wenlong and Yang, Zhengyang and Yao, Hongwei and Zhang, Zhongtao},
title = {Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy},
journal = {Research},
year = {2024},
volume = {7},
doi = {10.34133/research.0488}
}
EUVIMED